BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19479612)

  • 1. CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies.
    Geissinger E; Bonzheim I; Roth S; Rosenwald A; Müller-Hermelink HK; Rüdiger T
    Leuk Lymphoma; 2009 Jun; 50(6):1010-6. PubMed ID: 19479612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
    Jiang L; Yuan CM; Hubacheck J; Janik JE; Wilson W; Morris JC; Jasper GA; Stetler-Stevenson M
    Br J Haematol; 2009 Apr; 145(2):173-9. PubMed ID: 19236377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the tumor cells in peripheral T-cell lymphomas by combined polymerase chain reaction-based T-cell receptor beta spectrotyping and immunohistological detection with T-cell receptor beta chain variable region segment-specific antibodies.
    Geissinger E; Bonzheim I; Krenács L; Roth S; Ströbel P; Ott G; Reimer P; Wilhelm M; Müller-Hermelink HK; Rüdiger T
    J Mol Diagn; 2005 Oct; 7(4):455-64. PubMed ID: 16237215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.
    Kanavaros P; Boulland ML; Petit B; Arnulf B; Gaulard P
    Leuk Lymphoma; 2000 Jul; 38(3-4):317-26. PubMed ID: 10830738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of CD52 in peripheral T-cell lymphoma.
    Piccaluga PP; Agostinelli C; Righi S; Zinzani PL; Pileri SA
    Haematologica; 2007 Apr; 92(4):566-7. PubMed ID: 17488672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell and T/natural killer-cell lymphomas involving ocular and ocular adnexal tissues: a clinicopathologic, immunohistochemical, and molecular study of seven cases.
    Coupland SE; Foss HD; Assaf C; Auw-Haedrich C; Anastassiou G; Anagnostopoulos I; Hummel M; Karesh JW; Lee WR; Stein H
    Ophthalmology; 1999 Nov; 106(11):2109-20. PubMed ID: 10571346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nodal peripheral T-cell lymphomas correspond to distinct mature T-cell populations.
    Geissinger E; Bonzheim I; Krenács L; Roth S; Reimer P; Wilhelm M; Müller-Hermelink HK; Rüdiger T
    J Pathol; 2006 Oct; 210(2):172-80. PubMed ID: 16924587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD52 expression in non-mycotic T- and NK/T-cell lymphomas.
    Chang ST; Lu CL; Chuang SS
    Leuk Lymphoma; 2007 Jan; 48(1):117-21. PubMed ID: 17325855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD30 Expression by B and T Cells: A Frequent Finding in Angioimmunoblastic T-Cell Lymphoma and Peripheral T-Cell Lymphoma-Not Otherwise Specified.
    Onaindia A; Martínez N; Montes-Moreno S; Almaraz C; Rodríguez-Pinilla SM; Cereceda L; Revert JB; Ortega C; Tardio A; González L; García S; Camacho FI; González-Vela C; Piris MA
    Am J Surg Pathol; 2016 Mar; 40(3):378-85. PubMed ID: 26574847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of mature T-cell and NK-cell lymphoma with CD30 expression based on latest WHO classification].
    Feng Y; Fu J; Yan S; Ling Y; Huang Y; Cai M; Rao H
    Zhonghua Bing Li Xue Za Zhi; 2014 Aug; 43(8):508-11. PubMed ID: 25346118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of CD52 on plasma cells in plasma cell proliferative disorders.
    Kumar S; Kimlinger TK; Lust JA; Donovan K; Witzig TE
    Blood; 2003 Aug; 102(3):1075-7. PubMed ID: 12714489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral T-cell lymphoma--not otherwise specified.
    Savage KJ; Ferreri AJ; Zinzani PL; Pileri SA
    Crit Rev Oncol Hematol; 2011 Sep; 79(3):321-9. PubMed ID: 20702104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
    Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D
    Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunophenotype Expression Change From CD52+ to CD52- on Erythrodermic Peripheral T-cell Lymphoma, Not Otherwise Specified After Treatment With Alemtuzumab.
    Dhandha MM; Sufficool KE; Vidal CI; Robbins KJ; Fesler MJ; Batanian JR; Hurley MY
    Am J Dermatopathol; 2018 Jul; 40(7):547-550. PubMed ID: 28937435
    [No Abstract]   [Full Text] [Related]  

  • 15. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
    Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
    Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The frequency of immunoglobulin heavy chain gene and T-cell receptor gamma-chain gene rearrangements and Epstein-Barr virus in ALK+ and ALK- anaplastic large cell lymphoma and other peripheral T-cell lymphomas.
    Tan BT; Seo K; Warnke RA; Arber DA
    J Mol Diagn; 2008 Nov; 10(6):502-12. PubMed ID: 18832464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology.
    Fitzpatrick MJ; Massoth LR; Marcus C; Vergilio JA; Severson E; Duncan D; Ramkissoon SH; Hasserjian RP; Kim AS; Sohani AR; Williams EA; Nardi V
    Am J Surg Pathol; 2021 Jul; 45(7):895-904. PubMed ID: 34105517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High intratumoural galectin-1 expression predicts adverse outcome in ALK
    Holst JM; Ludvigsen M; Hamilton-Dutoit SJ; Bendix K; Plesner TL; Nørgaard P; Møller MB; Steiniche T; Rabinovich GA; d'Amore F; Pedersen MB
    Hematol Oncol; 2020 Feb; 38(1):59-66. PubMed ID: 31834627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
    Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS
    Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathobiology and molecular profiling of peripheral T-cell lymphomas.
    de Leval L; Gaulard P
    Hematology Am Soc Hematol Educ Program; 2008; ():272-9. PubMed ID: 19074096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.